Skip to main content
Menu Close
Home
Presented by
  • Neurology Reviews
  • Register or Login
Home
Full Menu Full Menu
  • Clinical Topics
  • MD-IQ
  • Multiple Sclerosis
  • Supplements
  • Video

News

Early intensive treatment of MS may benefit patients

Author:
Jake Remaly
Publish date: February 18, 2019

Real-world population-based cohort study finds better outcomes at 5 years with first-line treatment with a high-efficacy therapy.

  • Read More

News

DMTs, stem cell transplants both reduce disease progression in MS

Author:
Erik Greb

First- and second-line therapies reduce the risk of conversion to secondary progressive MS, and stem cell...

  • Read More

MD IQ

Quiz: Immunopathogenesis, diagnosis, and treatment of MS

Conference Coverage

Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively

BERLIN—Autologous hematopoietic stem cell transplantation (HSCT) could prevent disease activity and promote functional...

  • Read More

Conference Coverage

Interferon Beta May Not Affect Pregnancy Outcomes in MS

BERLIN—European registry data do not support the hypothesis that exposure to interferon beta before conception or during...

  • Read More

News

Daclizumab beta may be superior to interferon beta on MS disability progression

Author:
Erik Greb

A post hoc analysis indicates that daclizumab beta has superior efficacy, compared with interferon beta-1a, regardless of patients’ baseline...

  • Read More

News

Does rituximab delay disability progression in patients with secondary progressive MS?

Author:
Jake Remaly

Patients with secondary progressive MS who are treated with rituximab off label may accrue less disability during follow-up, compared with matched...

  • Read More

News

Integrated analysis suggests cladribine’s safety in MS

Author:
Erik Greb

Cladribine is not associated with an increased risk of infections or malignancy, and treatment-induced lymphopenia is transient.

  • Read More

News

Food allergies linked to increased MS relapses, lesions

Author:
Andrew D. Bowser

Patients with food allergies had more MS relapses and greater odds of further nerve damage.

  • Read More

Conference Coverage

Real-world data reveal long-lasting effects achieved with RRMS treatments

Author:
Sara Freeman
Publish date: December 13, 2018

BERLIN – Real-world data provide reassurance that currently used DMTs help reduce the risk of relapse in...

  • Read More

Article

Virus-Specific T-Cell Infusions May Resolve Progressive Multifocal Leukoencephalopathy

Infusion of allogeneic BK virus-specific T cells may be an effective treatment for patients with progressive multifocal...

  • Read More

Conference Coverage

Dietary sodium still in play as a potential MS risk factor

Author:
Kari Oakes
Publish date: December 7, 2018

BERLIN – High-salt diets decimate Lactobacillus species, with downstream immune effects.

  • Read More

MD IQ

Quiz: MS & optic neuritis

Conference Coverage

Breastfeeding with MS: Good for mom, too

Author:
Kari Oakes

BERLIN – Questions remain, but exclusive breastfeeding acts like a “temporary treatment” against multiple...

  • Read More

News

Stroke, arterial dissection events reported with Lemtrada, FDA says

Author:
Heidi Splete

Rare but serious events described in multiple sclerosis patients given alemtuzumab (Lemtrada) prompts new warning.

  • Read More

Conference Coverage

Fatigue in MS: Common, often profound, tough to treat

Author:
Kari Oakes

BERLIN – Cognitive behavioral therapy carries the best evidence to treat MS-related fatigue.

  • Read More

Conference Coverage

Particular lesions early after CIS predict long-term MS disability

Author:
Sara Freeman
Publish date: November 27, 2018

BERLIN – Early infratentorial and deep white matter lesions after a clinically isolated syndrome were associated...

  • Read More

Article

Panel Provides Recommendations for Managing Cognitive Changes in MS

The National Multiple Sclerosis (MS) Society has developed recommendations for the identification and management of...

  • Read More

Conference Coverage

MS disease activity returns in one-third after fingolimod withdrawal

Author:
Sara Freeman

BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...

  • Read More

Conference Coverage

  • Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
  • Interferon Beta May Not Affect Pregnancy Outcomes in MS
  • Real-world data reveal long-lasting effects achieved with RRMS treatments
    Publish date: December 13, 2018
  • Dietary sodium still in play as a potential MS risk factor
    Publish date: December 7, 2018
  • Breastfeeding with MS: Good for mom, too
more

Multimedia

  • John DeLuca, PhD
    Publish date: June 13, 2018
  • Global MS trends: A chaotic picture with risk as the central theme
    Publish date: June 2, 2018
  • Dr. Bowling
    Focus on preventing comorbidities in MS, physician urges
    Publish date: June 2, 2018
Visit our multimedia library

Immunopathogenesis, diagnosis, and treatment of MS

Question 1 of 5

Although the true etiology of multiple sclerosis (MS) remains unknown, it is believed to be caused by immune dysregulation triggered by genetic and environmental factors, such as _______________.

Vitamin A deficiency

Epstein-Barr virus infection

A cold climate

We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.

Whitelist MDedge.com
Close

This Publication

  • About Us
  • About This Site
  • Privacy Policy

Top Sections

  • Conference Coverage
  • Clinical Topics

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2019 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer and privacy policy.

click me
Menu Menu Presented by
  • Register or Login
Menu Close
Register or Login
  • Clinical Topics
  • Conference Coverage
  • MD-IQ
  • Multiple Sclerosis

More

  • Neurology Reviews